Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned

This article was originally published in The Pink Sheet Daily

Executive Summary

The global generics firm will rebrand Matrix, its Indian arm, as "Mylan," as it anticipates launching its prescription products in India under the Mylan label.

You may also be interested in...



Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA

Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.

After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout

MUMBAI - The potential of the Indian pharmaceutical market to double from the present $8 billion to $15 billion in the next five years led Abbott last week to strike the most richly valued deal for Piramal Healthcare's generic drug businesses, but the action for a share of the Indian market is set to accelerate further as Mylan - the third largest generic company in the world and the largest in the U.S. with sales exceeding $5 billion - is preparing to enter the Indian formulations market

Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on

MUMBAI - Prospects for strong growth in the global generic biologics space in the next 10 years has brought together the world's third-largest generic drug maker Mylan and India's biotechnology company Biocon. The two signed a comprehensive deal that will share development and certain other costs to bring biologic drugs to the market

Topics

UsernamePublicRestriction

Register

PS072300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel